These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 14767299

  • 1. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 2. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.
    N Engl J Med; 1998 Feb 26; 338(9):557-63. PubMed ID: 9475762
    [Abstract] [Full Text] [Related]

  • 3. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM, Runken MC, Grogg AL, Shah MB.
    Am J Manag Care; 2007 Feb 26; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [Abstract] [Full Text] [Related]

  • 4. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 26; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar 26; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 6. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
    Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher J.
    Eur Urol; 2000 May 26; 37(5):528-36. PubMed ID: 10765090
    [Abstract] [Full Text] [Related]

  • 7. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr 26; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 8. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM.
    BJU Int; 2006 Apr 26; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [Abstract] [Full Text] [Related]

  • 9. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May 26; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 10. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI, Chang HS, Kim BK, Park CH.
    Urology; 2006 Nov 26; 68(5):1015-9. PubMed ID: 17095071
    [Abstract] [Full Text] [Related]

  • 11. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 26; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 12. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
    Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J.
    Urology; 2000 Oct 01; 56(4):610-6. PubMed ID: 11018616
    [Abstract] [Full Text] [Related]

  • 13. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov 01; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 14. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.
    Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG, MTOPS RESEARCH Group.
    J Urol; 2006 Apr 01; 175(4):1422-6; discussion 1426-7. PubMed ID: 16516013
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
    Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    Urology; 2001 Jun 01; 57(6):1073-7. PubMed ID: 11377309
    [Abstract] [Full Text] [Related]

  • 16. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH, Meehan A, Lee M, Penson DF, Wessells H.
    J Urol; 2005 Mar 01; 173(3):903-7. PubMed ID: 15711315
    [Abstract] [Full Text] [Related]

  • 17. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC, Davis EA, Shah MB, Lin PJ.
    Am J Manag Care; 2008 May 01; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [Abstract] [Full Text] [Related]

  • 18. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 10; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 20. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.
    Roehrborn CG.
    Urology; 2002 Jun 10; 59(6):811-5. PubMed ID: 12031358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.